1. Varadhachary GR, Raber MN. Cancer of unknown primary site. N Engl J Med 2014;371:757–765.
2. Pavlidis N. Cancer of unknown primary: biological and clinical characteristics. Ann Oncol 2003;14(Suppl 3):iii11–iii18.
3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:7–34.
4. Vajdic CM, Er CC, Schaffer A, et al. An audit of cancer of unknown primary notifications: a cautionary tale for population health research using cancer registry data. Cancer Epidemiol 2014;38:460–464.
5. Brustugun OT, Helland Å. Rapid reduction in the incidence of cancer of unknown primary. A population-based study. Acta Oncol 2014;53:134–137.
8. Sève P, Billotey C, Broussolle C, Dumontet C, Mackey JR. The role of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site. Cancer 2007;109:292–299.
9. Rudmik L, Lau HY, Matthews TW, et al. Clinical utility of PET/CT in the evaluation of head and neck squamous cell carcinoma with an unknown primary: a prospective clinical trial. Head Neck 2011;33:935–940.
10. Oien KA. Pathologic evaluation of unknown primary cancer. Semin Oncol 2009;36:8–37.
11. Su AI, Welsh JB, Sapinoso LM, et al. Molecular classification of human carcinomas by use of gene expression signatures. Cancer Res 2001;61:7388–7393.
13. Weiss LM, Chu P, Schroeder BE, et al. Blinded comparator study of immunohistochemical analysis versus a 92-gene cancer classifier in the diagnosis of the primary site in metastatic tumors. J Mol Diagn 2013;15:263–269.
14. Fizazi K, Greco FA, Pavlidis N, et al. Cancers of unknown primary site: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015;26(Suppl 5):v133–v138.
15. Culine S, Kramar A, Saghatchian M, et al. Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol 2002;20:4679–4683.
16. Golfinopoulos V, Pentheroudakis G, Salanti G, Nearchou AD, Ioannidis JP, Pavlidis N. Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: multiple-treatments meta-analysis. Cancer Treat Rev 2009;35:570–573.
17. Hayashi H, Kurata T, Takiguchi Y, et al. Randomized phase II trial comparing site-specific treatment based on gene expression profiling with carboplatin and paclitaxel for patients with cancer of unknown primary site. J Clin Oncol 2019;37:570–579.
18. Fizazi K, Maillard A, Penel N, et al. A phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04). Ann Oncol 2019;30(Suppl 5):v851.
20. Hainsworth JD, Meric-Bernstam F, Swanton C, et al. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an Open-Label, phase IIa multiple basket study. J Clin Oncol 2018;36:536–542.
21. Fader AN, Roque DM, Siegel E, et al. Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2/neu. J Clin Oncol 2018;36:2044–2051.
22. Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol 2020;21:271–282.
25. Ross JS, Wang K, Gay L, et al. Comprehensive genomic profiling of carcinoma of unknown primary site: new routes to targeted therapies. JAMA Oncol 2015;1:40–49.
28. Gay LM, Fabrizio D, Frampton GM, et al. Mutational burden of tumors with primary site unknown. J Clin Oncol 2017;35(Suppl 15):3039.
29. Krämer A, Losa F, Gay LM, et al. Comprehensive profiling and molecularly guided therapy (MGT) for carcinomas of unknown primary (CUP): CUPISCO: a phase II, randomised, multicentre study comparing targeted therapy or immunotherapy with standard platinum-based chemotherapy. Ann Oncol 2018;29(Suppl 8):viii146.
30. Ross JS, Sokol ES, Moch H, et al. Comprehensive genomic profiling of carcinoma of unknown primary origin: retrospective molecular classification considering the CUPISCO study design. Oncologist 2021;26:e394–e402.